Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
作者信息
Reda Gianluigi, Cassin Ramona, Dovrtelova Gabriela, Matteo Cristina, Giannotta Juri, D'Incalci Maurizio, Cortelezzi Agostino, Zucchetti Massimo
机构信息
Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italy
Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italy.
出版信息
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
Abstract
摘要
相似文献
1
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.维奈克拉可穿透脑脊液，对合并中枢神经系统受累的慢性淋巴细胞白血病可能有效。
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
2
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.超声检查对复发/难治性慢性淋巴细胞白血病患者维奈克拉治疗的反应评估
Leuk Res. 2021 Jan;100:106488. doi: 10.1016/j.leukres.2020.106488. Epub 2020 Nov 30.
3
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
4
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
5
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.使用维奈托克治疗的慢性淋巴细胞白血病患者获得性血管性血友病综合征的缓解。
Leuk Lymphoma. 2019 Dec;60(12):3078-3080. doi: 10.1080/10428194.2019.1612063. Epub 2019 May 20.
6
Venetoclax (Venclexta) for chronic lymphocytic leukemia.维奈克拉（维可来）用于治疗慢性淋巴细胞白血病。
Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.
7
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.维奈托克用于接受一种以上B细胞受体途径抑制剂治疗后病情进展的慢性淋巴细胞白血病患者。
Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.
8
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.维奈克拉：一种用于治疗淋巴系统恶性肿瘤的首创口服 BCL-2 抑制剂。
Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.
9
Pairing obinutuzumab with venetoclax in relapsed CLL.在复发的慢性淋巴细胞白血病中，将奥妥珠单抗与维奈克拉联合使用。
Leuk Lymphoma. 2024 May;65(5):543-545. doi: 10.1080/10428194.2024.2323682. Epub 2024 Mar 18.
10
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.维奈托克治疗既往治疗的慢性淋巴细胞白血病患者。
Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. doi: 10.1158/1078-0432.CCR-16-0955. Epub 2017 Jan 18.
引用本文的文献
1
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia.维奈克拉联合砷剂及全反式维甲酸治疗复发/难治性急性早幼粒细胞白血病患者
Blood Cancer J. 2025 Jul 21;15(1):124. doi: 10.1038/s41408-025-01336-3.
2
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.布鲁顿酪氨酸激酶（BTK）抑制剂与维奈克拉联用或不联用抗CD20单克隆抗体治疗复发或难治性套细胞淋巴瘤的疗效
Ann Hematol. 2025 Apr;104(4):2361-2371. doi: 10.1007/s00277-025-06379-x. Epub 2025 Apr 25.
3
Leukemia Cutis in a Patient with Acute Myeloid Leukemia Undergoing Azacitidine-Venetoclax: Case Presentation and Review of the Literature.接受阿扎胞苷-维奈克拉治疗的急性髓系白血病患者的皮肤白血病：病例报告及文献复习
Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025013. doi: 10.4084/MJHID.2025.013. eCollection 2025.
4
Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients.急性白血病患者脑脊液、骨髓和血浆中 venetoclax 浓度的配对比较。
Clin Transl Sci. 2024 Sep;17(9):e70006. doi: 10.1111/cts.70006.
5
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.慢性淋巴细胞白血病的髓外和结外表现——最新进展。
Ann Hematol. 2024 Sep;103(9):3369-3383. doi: 10.1007/s00277-024-05854-1. Epub 2024 Jul 25.
6
Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review. Venetoclax 在血液系统恶性肿瘤中的群体药代动力学模型：系统评价。
Drug Des Devel Ther. 2024 May 27;18:1771-1784. doi: 10.2147/DDDT.S458927. eCollection 2024.
7
A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1.一种联合使用凋亡诱导剂（TMZ、MTX 和阿糖胞苷）与 XPO1、Bcl-2 和 Mcl-1 抑制剂 Eltanexor（维奈托克和 A1210477）治疗胶质母细胞瘤的新方法。
Cells. 2024 Apr 4;13(7):632. doi: 10.3390/cells13070632.
8
Emerging roles of senolytics/senomorphics in HIV-related co-morbidities.衰老细胞清除剂/模拟物在与 HIV 相关的合并症中的新作用。
Biochem Pharmacol. 2024 Oct;228:116179. doi: 10.1016/j.bcp.2024.116179. Epub 2024 Mar 29.
9
Treatment strategy in chronic lymphocytic leukemia with symptomatic central nervous system involvement: A case report.慢性淋巴细胞白血病合并有症状中枢神经系统受累的治疗策略：一例报告
Clin Case Rep. 2023 Nov 9;11(11):e7965. doi: 10.1002/ccr3.7965. eCollection 2023 Nov.
10
Diagnosis and management of adult central nervous system leukemia.成人中枢神经系统白血病的诊断与管理
Blood Sci. 2023 May 30;5(3):141-149. doi: 10.1097/BS9.0000000000000162. eCollection 2023 Jul.
本文引用的文献
1
Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.机制型生理基于药代动力学模型在生物药剂学分类系统 IV 型化合物溶出度和食物效应中的应用——维奈托克的故事。
J Pharm Sci. 2018 Jan;107(1):495-502. doi: 10.1016/j.xphs.2017.09.027. Epub 2017 Oct 6.
2
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.健康志愿者中选择性BCL-2抑制剂维奈托克与华法林的药代动力学相互作用评估。
Clin Drug Investig. 2017 Mar;37(3):303-309. doi: 10.1007/s40261-016-0485-9.
3
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.新型BCL-2抑制剂维奈托克在复发或难治性慢性淋巴细胞白血病或非霍奇金淋巴瘤患者中的药代动力学
J Clin Pharmacol. 2017 Apr;57(4):484-492. doi: 10.1002/jcph.821. Epub 2016 Nov 15.
4
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.BCL2选择性抑制剂维奈托克通过一种不依赖TP53的机制诱导患者慢性淋巴细胞白血病（CLL）细胞快速发生凋亡。
Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11.
5
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.依鲁替尼反应性中枢神经系统受累于慢性淋巴细胞白血病。
Blood. 2016 May 12;127(19):2356-8. doi: 10.1182/blood-2016-02-697193. Epub 2016 Mar 18.
6
Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.慢性淋巴细胞白血病累及中枢神经系统的患病率及特征
Haematologica. 2016 Apr;101(4):458-65. doi: 10.3324/haematol.2015.136556. Epub 2016 Jan 27.
7
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
8
Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012.髓外慢性淋巴细胞白血病：1975 年至 2012 年报告病例的系统分析。
Leuk Res. 2014 Mar;38(3):299-303. doi: 10.1016/j.leukres.2013.08.009. Epub 2013 Sep 6.
9
Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review.伴有中枢神经系统累及的慢性淋巴细胞白血病：两例病例报告并文献复习
J Neurooncol. 2012 Jan;106(1):185-200. doi: 10.1007/s11060-011-0636-z. Epub 2011 Jul 17.
Zotero 插件